KAS
MRTX

Kemnay Advisory Services’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kemnay Advisory Services’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,457
Closed -$759K – 114
2020
Q4 		$759K Buy
+3,457
New +$747K 0.1% 75

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kemnay Advisory Services's MRTX Position: Q1 2021 in Review

Kemnay Advisory Services sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 3,457 shares — an estimated $759K sold.

Kemnay Advisory Services first reported a position in MRTX in Q4 2020 and held it in 1 quarter. The position peaked at $759K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Kemnay Advisory Services reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Kemnay Advisory Services sold 3,457 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $759K.
  • Kemnay Advisory Services first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Kemnay Advisory Services's Mirati Therapeutics, Inc. Common Stock position peaked at $759K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Kemnay Advisory Services's 13F filing for Q1 2021, filed 17 May 2021.